SCHEMBL7521701

SCHEMBL7521701

CCc1ccc(NC(=O)NC2=C(C)C(=O)SC2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.42
EPHX1 P07099 2/20 0.42
SMN1; SMN2 Q16637 7/20 0.40
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
HTT P42858 5/20 0.40
NPC1 O15118 5/20 0.40
RAB9A P51151 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 3/20 0.39
OPRM1 P35372 2/20 0.39
OPRD1 P41143 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CHRM1 P11229 1/20 0.39
SLC6A2 P23975 1/20 0.39
PDE4A P27815 1/20 0.39
ADRA1A P35348 1/20 0.39
PDE3A Q14432 1/20 0.39
NLRP3 Q96P20 1/20 0.39
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7523505 0.80 RAB9A (0.46) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7515289 0.77 MAPT (0.45) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7523794 0.75 EPHX2 (0.41) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7960293 0.73 RAB9A (0.48) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7523145 0.72 EPHX2 (0.51) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7524471 0.71 EPHX2 (0.41) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7516081 0.70 KMT2A (0.40) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL10619104 0.70 RORC (0.62) SMN1; SMN2MEN1KMT2ARAB9AMAPT
SCHEMBL8245794 0.70 RAB9A (0.44) EPHX2EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL7518027 0.70 RAB9A (0.45) EPHX2EPHX1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 EPHX2 1967/4885EPHX1 1453/4885SMN1; SMN2 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.